
    
      Following the 96-week double-blind study period (MK0518-071)(NCT00745823), subjects may
      enroll in an extension study (MK0518-071-10)(NCT00745823). From weeks 96 to 120, subjects'
      treatment assignments will remain as in the base study.

      From week 120 to 240, all subjects will receive open-label raltegravir (800 mg, once daily)
      in combination with TRUVADAâ„¢.
    
  